



Do You See the Signs?®

Enhance Your Practice



**Objective | Valid & Reliable | Efficient
Reimbursable | Secure**

A Digital Neurocognitive & Neurobehavioral Testing Platform
Coupled with 50+ Clinical & Quality (PQH9, GAD7) Rating Instruments

14+ Million Neurocognitive Tests Given ♦ 50+ Languages
Worldwide Use in over 50 Countries

Correlated to ApoE Polymorphisms, Metabolic Markers, Imaging
and Expert Peer-Reviewed Psychometric Properties

www.CNSVS.com • 888.750.6941

Begin a Free Evaluation Today!

Expand Your Clinic Services

Go to www.CNSVS.com...

& make your selection.

New to CNS VS

Take a Short Demo

Experience a 10 minute - 3 Test
Sample from Your Email

Register and


Start Now!

Test Remotely or In-Clinic Today
with 5 Trial Assessments

Simple Business Model: Free Training, Support,
Software and Upgrades. No Subscriptions or Start-
up Fees. *Only purchase economical assessments
as needed... volume discounts available.*

World Leaders in Telehealth, Remote and In-Clinic Neurocognitive & Neurobehavioral Testing

Expand Your Clinic's Reach



**In-Clinic
Testing**

**Telehealth &
Remote Testing**



**Digital
Brain Health
Assessment Tools...
CNS VS ADHD Toolset**

FDA Medical Device Registration Number: 3006559064



API Enabled

Enhance Your Telehealth Encounters with CNS Vital Signs!

CNS Vital Signs standardized neurocognitive testing is a non-invasive, reimbursable clinical procedure to efficiently and objectively assess a broad-spectrum of brain function domain performances under challenge (cognition stress test). Aiding in the measuring of important clinical symptoms, behaviors, and comorbidities salient to the evaluation and ongoing management of many neurological, psychiatric and other conditions. Serial evaluation of neurocognition can help patients and caregivers navigate problems related to daily living, school or vocational work environment.

A diagram showing a central brain icon surrounded by seven hexagonal boxes, each representing a neurocognitive domain. The boxes are arranged in a circle around the brain. The domains are: Learning and Memory (top), Complex Attention (top-right), Social Cognition (bottom-right), Perceptual-Motor Function (bottom), Language (bottom-left), Executive Function (top-left), and Recommended Neurocognitive Domains (center). The central box is highlighted in blue, while the others are light blue. The text 'Cannot be tested on a computer.' is written below the Language box.

Learning and Memory

Complex Attention

Social Cognition

Perceptual-Motor Function

Language
Cannot be tested on a computer.

Executive Function

Recommended Neurocognitive Domains

Abstract | Neurocognitive disorders—*including delirium, mild cognitive impairment, and dementia*—are associated with cognitive impairment, functional decline, and negative health-related outcomes. However, the

*** Adapted From: Perminder S. Sachdev, Deborah Blacker, Dan G. Blazer, Mary Ganguli, Dilip V. Jeste, Jane S. Paulsen & Ronald C. Petersen: Classifying neurocognitive disorders: the DSM-5 approach: Nature Reviews Neurology volume 10, pages 634–642 (2014)

The CNS Vital Signs results are presented in a **DOMAIN DASHBOARD** and **DETAILED TEST** report format immediately following the brief testing session.

Standardized evaluation of neurocognitive and behavioural issues provides a systematic and efficient method of collecting valid and reliable clinical measures currently recommended by most neuro-psych guidelines.

Altogether, CNS Vital Signs computerized testing can facilitate a more complete assessment and provide a basis for patient and family feedback. The colorful auto-scored reports are designed to present and share with patients, families, and caregivers.

Additional Clinical and Practice Benefits

- **Millisecond Precision**
- **Many Peer-Reviewed Publications** (Award Winning)
- **Embedded Test Validity Indicators**
- **Millions of Tests Given Worldwide Since 2006**
- **Over 50 Languages**
- **Unlimited Alternate Forms for Serial Testing**
- **No Ceiling Effect...** Open Ended Performance to Identify Superior Subjects
- **Modular...** Easily Configured Custom Testing Panels and Platform
- **Enhanced Auditability** with Automated Systematic Documentation
- **HIPAA Secure**, Data back-up and Data export
- **Broad Deployment...** Solutions for small, medium and large practices, integrated delivery systems, high security environments such as FDA sponsored clinical research, Military, VA Hospitals, Academic Medical Centers, across thousands of clinician and research users worldwide

Easy to Read... Immediate Reporting

Reports available in English, Spanish, Japanese, Korean, and Dutch.

CNS Vital Signs Report

Patient ID: PatientExample

Age: 50

Total Test Time: 39:07 (min:secs)

Test Date: March 28, 2021 09:20:03

Administrator: Technician

Language: English (United States)

CNSVS Duration: 38:16 (min:secs)

Version 4.0.94

Patient Profile:

Percentile Range

Standard Score Range

2

1

> 74

25 - 74

9 - 24

2 - 8

< 2

> 109

90 - 109

80 - 89

70 - 79

< 70

Domain Scores

Subject Score

Standard Score

Percentile

VI**

Above

Average

Low Average

Low

Very Low

Neurocognition Index (NCI)

NA

78

7

Yes

X

Composite Memory

94

93

32

Yes

X

Verbal Memory

52

99

47

Yes

X

Visual Memory

42

90

25

Yes

X

Psychomotor Speed

127

69

2

Yes

X

Reaction Time*

751

87

19

Yes

X

Complex Attention*

16

70

2

Yes

X

Cognitive Flexibility

22

70

2

Yes

X

Processing Speed

29

64

1

Yes

X

Executive Function

28

77

6

Yes

X

Social Acuity

7

90

25

Yes

X

Reasoning

10

116

86

Yes

X

Simple Attention

40

107

68

Yes

X

Motor Speed

98

84

14

Yes

X

Domain Dashboard:

Above average domain scores indicate a standard score (SS) greater than 109 or a Percentile Rank (PR) greater than 74, indicating a high functioning test subject. Average is a SS 90-109 or PR 25-74, indicating normal function. Low Average is a SS 80-89 or PR 9-24 indicating a slight deficit or impairment. Below Average is a SS 70-79 or PR 2-8, indicating a moderate level of deficit or impairment. Very Low is a SS less than 70 or a PR less than 2, indicating a deficit and impairment. Reaction times are in milliseconds. An * denotes that "lower is better", otherwise higher scores are better. Subject Scores are raw scores calculations generated from data values of the individual subtests.

VI** - Validity Indicator: Denotes a guideline for representing the possibility of an invalid test or domain score. "No" means a clinician should evaluate whether or not the test subject understood the test, put forth their best effort, or has a clinical condition requiring further evaluation.

Verbal Memory Test (VBM)

Score

Standard

Percentile

Correct Hits - Immediate

13

104

61

Correct Passes - Immediate

14

96

40

Correct Hits - Delay

9

93

32

Correct Passes - Delay

15

110

75

Visual Memory Test (VIM)

Score

Standard

Percentile

Correct Hits - Immediate

12

101

53

Correct Passes - Immediate

11

98

45

Correct Hits - Delay

9

86

18

Correct Passes - Delay

10

95

37

Finger Tapping Test (FTT)

Score

Standard

Percentile

Right Taps Average

50

86

18

Left Taps Average

48

85

16

Symbol Digit Coding (SDC)

Score

Standard

Percentile

Correct Responses

29

64

1

Errors*

0

110

75

Stroop Test (ST)

Score

Standard

Percentile

Simple Reaction Time*

231

102

55

Complex Reaction Time Correct*

542

91

27

Stroop Reaction Time Correct*

568

87

19

Stroop Commission Errors*

6

33

1

Shifting Attention Test (SAT)

Score

Standard

Percentile

Correct Responses

38

77

6

Errors*

10

84

14

Correct Reaction Time*

1360

77

6

Continuous Performance Test (CPT)

Score

Standard

Percentile

Correct Responses

40

103

58

Omission Errors*

0

103

58

Commission Errors*

0

107

68

Choice Reaction Time Correct*

491

83

13

Perception Of Emotions Test (POET)

Score

Standard

Percentile

Correct Responses

11

95

37

Average Correct Reaction Time*

1361

70

2

Omission Errors*

1

95

37

Commission Errors*

4

92

30

Positive Emotions

Score

Standard

Percentile

Correct Hits

6

106

66

Reaction Time*

1350

62

1

Negative Emotions

Score

Standard

Percentile

Correct Hits

5

88

21

Reaction Time*

1375

82

12

Reasoning Test (RT)

Score

Standard

Percentile

Correct Responses

12

117

87

Average Correct Reaction Time*

4284

110

75

Commission Errors*

2

115

84

Omission Errors*

1

102

55

4

Longitudinal Reports

CNS Vital Signs Graphical Report

Score Average

Average

Low Average

Low

Very Low

Neurocognition Index

Composite Memory

Verbal Memory

Visual Memory

Psychomotor Speed

Reaction Time

Complex Attention

Cognitive Flexibility

Processing Speed

Executive Function

Simple Attention

Motor Speed

• cognitive

2009-11-26 09:20:24

108

83

99

90

88

87

89

70

64

77

107

84

• cognitive

2010-10-16 08:11:16

97

118

106

122

87

92

99

89

76

89

107

100

• cognitive

2010-12-15 12:48:20

102

110

96

115

96

92

115

96

94

96

107

100

Neurocognition Index

Standard Score

2009-11-26

2010-10-16

2010-12-15

new

2009-01-10

2008-12-15

Composite Memory

Standard Score

2009-11-26

2010-10-16

2010-12-15

new

2009-01-10

2008-12-15

Neurocognition Index

Abstract Information

Visual Analogies

Progressively more difficult


Each is presented for 14.5 seconds

Non-verbal or visual-abstract reasoning is the process of perceiving issues and reaching conclusions through the use of symbols or generalizations rather than concrete factual information.

DOMAIN DASHBOARD

DETAILED TEST RESULTS

Longitudinal Reports



Find CNS Vital Signs Reimbursement & Brief Interpretation Guides at www.CNSVS.com

Test, Evaluate & Manage... Optimize Your Practice Processes

Test Evaluation Criteria: The CNS VS reports are logical and intuitive making the interpretation by a health professional relatively straightforward. CNS Vital Signs has taken a **LIFESPAN approach** collecting a **large peer neurocognitive normative reference group from ages 8 to 90**. The normative comparison helps clinicians grade the level of neurocognitive impairment and compare the evidence of cognitive decline from a previous level of performance which can help rule-in or rule-out certain clinical conditions, help determine the level of impairment or track disease progression or improvement. Clinical insight into the cognitive status of a patient can come from impairment in one or more cognitive domains. Like any laboratory test, an abnormal result should be the occasion for further evaluation.

1

Evaluate Validity: The **Validity Indicator (VI)** helps identify the possibility of an invalid test. Embedded measures help evaluate whether the patient is manipulating testing performance for a secondary gain, or they simply did not read the test instructions. Examples of secondary gain include drug or disability seeking, academic accommodation, malingering, symptom feigning, etc.

2

Evaluate Severity: The scores help identify cognitive deficits and their level of impairment. Assess even slight cognitive impairment (millisecond precision) providing immediate clinical insight into a patient's cognitive deficits and level of impairment. This gives patients, family members and caregivers knowledge of cognitive domains that underpin the ability to conduct activities of daily living.

3

Evaluate Pattern: Impairment pattern helps identify pathologies and possible comorbidities. The CNS VS cognitive pattern profiles (interpretation guide) may assist clinicians in the evaluation of neurological, psychiatric, and developmental disorders. CNS Vital Signs cognitive testing procedure provides valid and reliable clinical endpoints to help in the evaluation and management of patients.

4


Evaluate Longitudinally: Track disease progression, outcomes, or treatment effects. **Establish a baseline** and serially assess cognitive clinical endpoints to aid in the monitoring and management of many clinical conditions and treatments e.g., measure the response to disease and treatment like MS, AD/HD & stimulants, rehabilitation efforts, and used to measure clinical outcomes.

Testing performance should be reviewed with knowledge of a patient's history and physical or diagnostic interview, lab tests, etc. to understand the context of the possible cognitive deficits. **Examples of CNS Vital Signs use...**

- **Neurodegeneration** (Neurocognitive Disorder, MCI, Multiple Sclerosis, Parkinson's, Sleep, etc.)
- **Neurotraumatic** (mTBI, Concussion, TBI Rehabilitation)
- **Neurodevelopmental** (AD/HD, Asperger's, etc.)
- **Neuropsychiatric** (ADD, SUD, Bipolar, Depression, PTSD, Schizophrenia, Anxiety, etc.)
- **Other:** COVID, HIV-HAND, Cancer Cognition, Chronic Pain Fibro-Fog, Encephalopathy, Metabolic / Diabetes, Cardiovascular, Prion or Lyme Disease, Human Performance, Neurotoxicity, Diet & Exercise, Medication Effects, etc.

Easily Graph Longitudinal Results

Executive Function













One Key Difference – Measuring Cognitive Speed... "CNS Vital Signs is sensitive in detecting cognitive impairment ...uses computerized forms of traditional tests such as Symbol Digit Modalities and Stroop ...are easy to use, require significantly less time to administer, produce instant scoring and can incorporate alternate forms, necessary to minimize learning effect on follow-up. **...also, the capacity to accurately-automatically quantify "speed factor" via multiple parameters such as reaction time, psychomotor speed, and processing speed, increasing their sensitivity in detecting even subtle changes in information processing speed.**" **

**Cognitive Impairment in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients: Efficacy of a Computerized Cognitive Screening Battery; ISRN Neurology, 2014 Mar 13;2014:

10 Normed Neurocognitive Tests... 50+ Rating Scales

Fully Integrated System with VS4 Local Computer Software and Cloud-Based Online Testing

Verbal Memory (VBM) <i>Approx. 3 Minutes</i>		<ul style="list-style-type: none"> Learning Words Memory for Words Word Recognition Immediate and Delayed Recall 	<p><i>Computerized versions of VENERABLE NEUROPSYCHOLOGICAL TESTS. Measures the SPEED and ACCURACY of a patient's response. TOTAL TEST TIME depends on the number of tests and rating instruments selected. Modular testing panels can be custom configured according to clinical practice or research needs.</i></p> <p>CNS Vital Signs assessment platform includes 50+ medical and health rating instruments helping identify and systematically document PATIENT and INFORMANT ratings of symptoms, behaviors and comorbidities.</p> <p>Pediatric - Adolescent Instruments:</p> <p>Developmental - Mental Health</p> <ul style="list-style-type: none"> Pediatric Symptom Checklist (PSC-35, Youth and PSC-17) Vanderbilt ADHD Diagnostic Parent & Teacher Rating Scales Vanderbilt Assessment Follow-up Parent & Teacher Rating Scales PHQ-9 Depression & GAD-7 Anxiety DASS - Depression, Anxiety and Stress Scale 21 & 42 (14 years of age and up) Screen for Child Anxiety Related Disorders (SCARED) Child & Parent Version Social Anxiety Scale for Children and Adolescents (SASCA) <p>Targeted Instruments</p> <ul style="list-style-type: none"> Child Obsessive-Compulsive Disorder Inventory (OCD-C) Childhood Cancer Survivor Study Neurocognitive Questionnaire (CCSS) Neurobehavioral Symptom Inventory (NSI) DSM -5 PTSD Checklist (PCL-5) & Stressor Specific (PCL-S) <p>Substance Abuse - SBIRT</p> <ul style="list-style-type: none"> Drug Use Questionnaire (DAST) Alcohol Use Disorders Identification Test (AUDIT) <p>Adult Instruments:</p> <p>Health Risk - Mental Health</p> <ul style="list-style-type: none"> Patient Health Questionnaire (PHQ-9) General Anxiety Disorder (GAD-7) DASS - Depression, Anxiety and Stress Scales 21 & 42 Zung Self-Rating Depression & Anxiety Scales Stanford Geriatric Depression Scales (SGDS) 15 & 25 <p>Targeted Instruments</p> <ul style="list-style-type: none"> Quality of Life Medical Outcomes Survey (MOS) SF-36 Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist DSM-5 PTSD Checklist (PCL-5), also the Civilian (PCL-C), Stressor Specific (PCL-S) and Military (PCL-M) Fall Risk Questionnaire (FRQ) Health Assessment Questionnaire (HAQ) Disability Scale Modified Fatigue Impact Scale (MFIS) Neurobehavioral Symptom Inventory (NSI) Dizziness Handicap Inventory (DHI) Head Injury Questionnaire (HIQ) Memory Questionnaire (MEMQ) Adult Obsessive-Compulsive Disorder Inventory (OCD-A) MHE Questionnaire Combat Exposure Scale (CES) Life Events Checklist (LEC) Deployment Risk and Resiliency Inventories Life Habits Checklist Medical Symptoms Questionnaire (Past 30 Days) and (Past 48 Hours) <p>Sleep</p> <ul style="list-style-type: none"> Epworth Sleepiness Scale (ESS) Pittsburgh Sleep Quality Index (PSQI) Sedation Scale (SS) Alertness Rating Scale (ARS) <p>Substance Abuse - SBIRT</p> <ul style="list-style-type: none"> Drug Use Questionnaire (DAST) Alcohol Use Disorders Identification Test (AUDIT) <p>Pain</p> <ul style="list-style-type: none"> Numeric Pain Scale Pain Catastrophizing Scale (PCS)
Visual Memory (VIM) <i>Approx. 4 Minutes</i>		<ul style="list-style-type: none"> Learning Shapes Memory for Shapes Shapes Recognition Immediate and Delayed Recall 	
Finger Tapping (FTT) <i>Approx. 2 Minutes</i>		<ul style="list-style-type: none"> Motor Speed Fine Motor Control 	
Symbol Digit Coding (SDC) <i>Approx. 4 Minutes</i>		<ul style="list-style-type: none"> Complex Information Processing Accuracy Complex Attention Visual-Perceptual Speed Information Processing Speed 	
Stroop Test (ST) <i>Approx. 4 - 5 Minutes</i>		<ul style="list-style-type: none"> Simple Reaction Time Complex Reaction Time Stroop Reaction Time Inhibition / Disinhibition Frontal or Executive Skills 	
Shifting Attention (SAT) <i>Approx. 2.5 Minutes</i>		<ul style="list-style-type: none"> Executive Function Shifting Sets: Rules, Categories, & Rapid Decision Making Reaction Time 	
Continuous Performance (CPT) <i>Approx. 5 Minutes</i>		<ul style="list-style-type: none"> Sustained Attention Choice Reaction Time Impulsivity 	
Perception of Emotions (POET) <i>Approx. 2 Minutes</i>		<ul style="list-style-type: none"> Social Cognition or Emotional Acuity Choice Reaction Time 	
Non-Verbal Reasoning (NVRT) <i>Approx. 3.5 Minutes</i>		<ul style="list-style-type: none"> Reasoning Reasoning Recognition Speed 	
4-Part Continuous Performance (FPCPT) <i>Approx. 7 Minutes</i>		<ul style="list-style-type: none"> Sustained Attention Working Memory 	

Efficient testing for your patient needs and time constraints.

Case Examples: MCI, DSM-5 Neurocognitive Disorder, Early Intervention

Amnestic MCI Baseline: 60-Year-Old Male Initial MMSE 25*

Patient Profile:	Percentile Range				Standard Score Range				
	Standard Score Range				Percentile				
	Subject Score	Standard Score	Percentile	VI**	> 74	25 - 74	9 - 24	2 - 8	< 2
Domain Scores	Subject Score	Standard Score	Percentile	VI**	Above	Average	Low Average	Low	Very Low
Neurocognition Index (NCI)	NA	83	1	No					X
Composite Memory	72	80	1	Yes					X
Verbal Memory	36	57	1	Yes					X
Visual Memory	36	73	5	Yes					X
Psychomotor Speed	178	116	86	Yes	X			X	
Reaction Time*	710	99	47	Yes		X			
Complex Attention*	118	104	1	No					X
Cognitive Flexibility	27	92	30	Yes		X			
Processing Speed	47	106	63	Yes		X			
Executive Function	29	92	30	Yes		X			
Simple Visual Attention	-66	-87.4	1	No					X
Motor Speed	130	121	92	Yes	X				


Joe, a 60-year-old male is presenting with memory and concentration concerns and was given CNS Vital Signs Clinical Battery and scored below average compared to his peers in 6 of 11 cognitive domains. His lowest scores were in domains sensitive to amnestic (memory related) MCI.

After considering the H&P, lab results, patient and informant memory questionnaire, sleep scales and the cognitive test results; Joe was referred for a sleep study. Later he was prescribed CPAP and appropriate therapy.


CNS Vital Signs allowed a fine characterization of Joe's clinical course, including apparent variation due to compliance with therapy. Patient and wife were positively influenced by revelation of objective cognitive testing performance, which proved useful in demonstrating probable effects of compliance.

Amnestic MCI Longitudinal View: 60-Year-Old Male

NCI - Neurocognition Index



CNS VS Correlation to Alzheimer's ApoE Polymorphisms



Average **Standard Scores** for cognitive functions in particular groups of *ApoE* gene polymorphisms.

Correlation to Biological Markers

Polymorphisms of *apolipoprotein E* gene and cognitive functions of postmenopausal women, measured by battery of computer tests – Central Nervous System Vital Signs

Iwona BOJAR¹, Angelina WÓJCİK-FATLA¹, Alfred OWOC², Andrzej LEWINSKI³

...Study included 107 postmenopausal women between the ages of 52 and 65 (mean 56.6 ± 3.5)

...Subjects were qualified as "normal" with MOCA scores between 26 and 30

...Findings revealed ApoE polymorphisms correlated to levels of cognitive function where as expected ε3/ε4, or ε4/ε4 scored poorly while ε2/ε3 groups scored much better.

Adapted from: Bojar, Iwona & Wójcik-Fatla, Angelina & Owoc, Alfred & Lewiński, Andrzej. (2012). Polymorphisms of apolipoprotein E gene and cognitive functions of postmenopausal women, measured by battery of computer tests - Central Nervous System Vital Signs. *Neuroendocrinology letters*. 33. 385-92.

"...increasing emphasis on early intervention to prevent or postpone dementia..."*
makes CNS Vital Signs a VALUABLE TOOL for your PRACTICE!**

Case Examples: AD/HD, Medication Effects

AD/HD Baseline: 16-Year-Old Female

Patient Profile:	Percentile Range				Standard Score Range									
	Subject Score	Standard Score	Percentile	VI**	> 109	90 - 109	80 - 89	70 - 79	< 70	> 74	25 - 74	9 - 24	2 - 8	< 2
Domain Scores					Above	Average	Low Average	Low	Very Low					
Neurocognition Index (NCI)	NA	38	14	No					X					
Composite Memory	95	88	23	Yes			X							
Verbal Memory	49	87	19	Yes			X							
Visual Memory	46	95	37	Yes		X								
Psychomotor Speed	173	98	45	Yes		X								
Reaction Time*	591	107	68	Yes		X								
Complex Attention*	77	-139	0	No										X
Cognitive Flexibility	2	39	1	Yes										X
Processing Speed	44	89	9	Yes				X						X
Executive Function	10	47	1	Yes										X
Simple Visual Attention	0	-345	0	No										X
Motor Speed	115	100	50	Yes		X								

Janie, a sixteen-year-old girl struggling in school was given CNS Vital Signs VS4 Clinical Battery and scored below average compared to her peers in 7 of 11 cognitive domains (pre-dose). Her lowest scores were in domains represented by venerable frontal lobe tests.

After reviewing H&P, all test results, the PCS -pediatric symptom checklist & the Vanderbilt AD/HD rating scales; Janie was given a prescription medication. Four weeks later she was administered the test again after being on medication (post dose).

AD/HD Post Medication: 16-Year-Old Female

Patient Profile:	Percentile Range				Standard Score Range									
	Subject Score	Standard Score	Percentile	VI**	> 109	90 - 109	80 - 89	70 - 79	< 70	> 74	25 - 74	9 - 24	2 - 8	< 2
Domain Scores					Above	Average	Low Average	Low	Very Low					
Neurocognition Index (NCI)	NA	110	75	Yes	X									
Composite Memory	98	97	42	Yes		X								
Verbal Memory	60	128	97	Yes	X									
Visual Memory	38	72	4	Yes				X						
Psychomotor Speed	140	118	99	Yes	X									
Reaction Time*	801	106	66	Yes		X								
Complex Attention*	14	117	87	Yes	X									
Cognitive Flexibility	27	116	88	Yes	X									
Processing Speed	34	106	66	Yes		X								
Executive Function	28	116	86	Yes		X								
Simple Visual Attention	38	106	66	Yes		X								
Motor Speed	105	118	88	Yes	X									

The CNS Vital Signs report is available immediately after the testing session ends and provides utility as a tool for assessing academic and vocational accommodations, secondary gain, as well as measuring medication effect and helping clinicians tailor medications to achieve optimal clinical benefit.

Psychometric Measures for Treatment Response

ORIGINAL CONTRIBUTION
Effect of Methylphenidate on Neurocognitive Test Battery
An Evaluation According to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Subtype
Sibel Donuk, MD,* Eyyup Sabri Ercan, MD,† Ulku Aydin Ardic, MD,‡ Deniz Yuce, MD,§
Elif Ercan, PhD,§ and Melis Apici, BS||

Adapted From:
Effect of Methylphenidate on
Neurocognitive Test Battery;
Journal of Clinical Psychopharmacology;
Volume 34, Number 4, August 2014

Evaluate the neuropsychological characteristics of PI - predominantly inattentive, R - restrictive, and CB - combined (inattentive & hyperactive) AD/HD subtypes...

Comparisons of CNSVS Domain Scores Between the AD/HD Groups Before MPH Medication Administration

	PI	R	CB	Contro		
Baseline Measurements	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	P	Pairwise Comparisons
Neurocognition Index	87.62 (14.66)	90.71 (11.77)	90.25 (11.14)	96.91 (10.87)	<0.001*	(PI=R=CB) < control
Composite Memory	84.56 (21.86)	87.97 (19.5)	91.89 (20.92)	96.73 (18.82)	0.01	PI < control
Psychomotor speed	92.96 (10.49)	94.12 (10.87)	93.63 (12.54)	99.77 (16.58)	<0.001	(PI=R=CB) < control
Reaction time	78.54 (21.63)	83.15 (18.42)	81.86 (16.49)	83.26 (28.57)	0.65*	
Complex attention	91.38 (24.6)	94.92 (16.81)	90.77 (18.41)	102.15 (12.45)	<0.001*	(PI=R=CB) < control
Cognitive flexibility	90.84 (16.15)	93.32 (15.51)	91.15 (14.1)	102.82 (15.28)	<0.001	(PI=R=CB) < control
Symbol Digit Coding (Processing Speed Domain)						
Correct responses	41.24 (12.73)	41.82 (13.8)	40.23 (12.36)	48.18 (11.77)	<0.001	(PI=R=CB) < control
Errors	0.92 (1.18)	1.09 (1.26)	1 (2.28)	3.6 (5.53)	<0.001*	(PI=R=CB) < control
Shifting Attention Test (Executive Function Domain)						
Correct responses	34.44 (10.09)	35.43 (11.33)	34.07 (9.95)	42.23 (9.98)	<0.001	(PI=R=CB) < control
Errors	15.34 (7.83)	15.71 (9.41)	17.52 (8.02)	11.55 (6.06)	<0.001*	(PI=R=CB) > control
Correct reaction time	1290.6 (133.52)	1224.91 (236.4)	1233.39 (175)	1188.6 (222.75)	0.01*	CB > control
CPT (Simple Attention Domain)						
CPT Correct	38.54 (2.61)	37.84 (5.25)	38.3 (2.71)	39.19 (1.14)	<0.001*	R > control
Omission	1.46 (2.61)	1.61 (2.15)	1.7 (2.71)	0.81 (1.14)	<0.001*	CB > control
Commission errors	3.42 (4.65)	11.59 (66.7)	3.99 (4.02)	1.71 (1.68)	<0.001*	R > control, CB > control
Choice RT correct	506.84 (79.92)	490.2 (100.28)	515.36 (81.96)	470.5 (68.55)	<0.001	PI < control

*The Welch ANOVA test was used for comparisons between diagnostic groups, and post hoc comparisons were performed with Tamhane's T2 test. All other comparisons were performed with the ANOVA test, and post hoc tests were performed with the Tukey test.

*** Attention-deficit/hyperactivity disorder (ADHD); Søren Dalsgaard; Eur Child Adolesc Psychiatry (2013) 22 (Suppl 1):S43-S48

*** **RESTRICTIVE (DSM-V):** If criterion A1 (inattention) is met, but no more than two symptoms from criterion A2 (hyperactivity / impulsivity) have been present for the past 6 months.

Comparisons After MPH Administration

PI	R	CB
Mean (SD)	Mean (SD)	Mean (SD)
95.53 (11.96)	98.66 (11.62)	97.38 (10)
81.27 (22.57)	85.59 (20.44)	85.9 (17.7)
98.88 (9.77)	99.8 (11.09)	99.73 (10.52)
88.25 (19.19)	89.88 (17.98)	86.43 (17.92)
105.51 (16.27)	108.53 (17.14)	107.58 (12.63)
104.77 (15.63)	108.42 (14.14)	106.58 (13.74)

...**Study included** 360 children and adolescents (277 boys, 83 girls) between 7 and 15 years of age who had been diagnosed with ADHD at the Department of Child and Adolescent Psychiatry using K-SADS-PL and DSM-IV

...**Subjects were** grouped according to ADHD subtypes as PI (n = 51), R (n = 65), and CB (n = 165). Seventy-nine healthy children were recruited into the study as the control group

...**Findings revealed controls scored better than ADHD subjects and ADHD subjects scored better on MPH than with no drug**

Case Examples: Concussion, mTBI, PTSD

mTBI / Concussion Post Injury: 20-Year-Old Male

Patient Profile:	Percentile Range				Standard Score Range									
	Subject Score	Standard Score	Percentile	VI**										
Domain Scores					Above	Average	Low Average	Low	Very Low					
Neurocognition Index (NCI)		85	16	Yes										
Composite Memory	102	103	58	Yes		X								
Verbal Memory	91	93	32	Yes		X								
Visual Memory	18	110	75	Yes	X									
Psychomotor Speed	174	93	32	Yes		X								
Reaction Time*	555	107	68	Yes		X								
Complex Attention*	21	86	1	Yes									X	
Cognitive Flexibility	26	83	1	Yes									X	
Processing Speed	48	79	8	Yes							X			
Executive Function	34	78	5	Yes							X			
Simple Visual Attention	40	108	70	Yes		X								
Motor Speed	124	105	63	Yes		X								

Following a collision in a club rugby match Paul, a 20-year-old college student, visited the ER complaining of a headache and nausea. Not having a cognitive baseline Paul was given CNS Vital Signs VS4 Clinical Battery (1st post injury). Compared to his peers he scored below average in 4 of 11 cognitive domains. His lowest scores were in domains represented by frontal lobe tests.

After examining Paul, and reviewing the CT scan, symptom scale as well as the cognitive test results; Paul was started on a concussion management protocol. Two weeks later after he was symptom free, he was administered the test again (2nd post injury). The CNS Vital Signs session and longitudinal reports were available immediately after the testing session allowing the clinician to evaluate and manage Paul efficiently at the office visit.

The CNS Vital Signs testing platform is designed to support TBI, mTBI and sports concussion guidelines.

mTBI / Concussion 2nd Post Injury: 20-Year-Old Male

Patient Profile:	Percentile Range				Standard Score Range									
	Subject Score	Standard Score	Percentile	VI**										
Domain Scores					Above	Average	Low Average	Low	Very Low					
Neurocognition Index (NCI)		113	81	Yes	X									
Composite Memory	115	130	98	Yes	X									
Verbal Memory	58	118	88	Yes	X									
Visual Memory	58	130	98	Yes	X									
Psychomotor Speed	201	110	76	Yes	X									
Reaction Time*	550	108	70	Yes		X								
Complex Attention*	3	110	78	Yes	X									
Cognitive Flexibility	55	108	70	Yes		X								
Processing Speed	65	100	60	Yes		X								
Executive Function	86	108	70	Yes		X								
Simple Visual Attention	40	108	70	Yes		X								
Motor Speed	136	115	84	Yes	X									



Correlation to Imaging Markers

Post Concussion Syndrome - PTSD




Examining Microstructural White Matter in Active-Duty Soldiers with a History of Mild Traumatic Brain Injury and Traumatic Stress

Method: Seventy-four active-duty U.S. soldiers with PTS (n = 16) and PTS with co-morbid history of mTBI (PTS/mTBI; n = 28) were compared to a military control group (n = 30). Participants received a battery of neurocognitive and clinical symptom measures. The number of abnormal DTI (diffusion tensor imaging) values was determined (>2 SDs from the mean of the control group) for fractional anisotropy (FA) and mean diffusivity (MD), and then compared between groups...

Results: The comorbid PTS/mTBI group had significantly greater traumatic stress, depression, anxiety, and post-concussive symptoms, and they performed worse on neurocognitive testing than those with PTS alone and controls. The groups differed greatly on several clinical variables, but contrary to what we hypothesized, they did not differ greatly on primary and exploratory analytic approaches of hetero-spatial whole brain DTI analyses.

Conclusion: In conclusion, our findings do not provide strong evidence of compromised white matter integrity between our clinical groups compared to controls using several analytic approaches. **In contrast, our groups were best categorized by robust differences in clinical symptoms and neurocognitive scores (i.e., CNS Vital Signs / TOMM).** As such, our findings suggest that psychological health conditions rather than pathoanatomical changes may be contributing to symptoms presented by soldiers with comorbid PTS and mTBI.

Adapted from: Dretsch, Michael N., Rael T. Lange, Jeffrey S. Katz, Adam Goodman, Thomas A. Daniel, Gopikrishna Deshpande, Thomas S. Denney, Grant L. Iverson, and Jennifer L. Robinson. 2017. "Examining Microstructural White Matter in Active-Duty Soldiers with a History of Mild Traumatic Brain Injury and Traumatic Stress." The Open Neuroimaging Journal



*Comparing symptom severity, neurocognitive functioning, and self-report measures of the control subjects and the... PCS-PTSD group (green stars). The significance threshold (0.05) is visible as a thick horizontal line. Control subjects exhibited significantly better neurocognitive performance, less sleepiness and anxiety, and less combat exposure. **PCS-PTSD subjects exhibited significantly worse neurocognitive performance and higher PCS symptom.**

*Adapted from: Human Brain Mapping 38:2843-2864 (2017); Compromised Hippocampus-Striatum Pathway as a Potential Imaging Biomarker of Mild-Traumatic Brain Injury and Posttraumatic Stress Disorder; Rangaprakash et al.

Add Brain Health Services to Your Practice



CNS Vital Signs Enabling MCI Guidelines

...and Efficient Collection of MIPS Quality Measures

SPECIAL ARTICLE

Neurology® 2019;93:705-713. doi:10.1212/WNL.00000000000008259

Quality improvement in neurology

Mild cognitive impairment quality measurement set

Norman L. Foster, MD, Mark W. Bondi, PhD, ABPP-CN, Rohit Das, MD, Mary Foss, Linda A. Hershey, MD, PhD, Joseph W. Shega, MD, MPH, MBA, Rebecca Logan, PA-C, MPAS, Carol Poole, Joseph W. Shega, MD, Joseph W. Shega, MD, MPH, MBA, Meredith Wicklund, MD, Melissa Yu, MD


- **MCI is clinically important**, but often not recognized... Since **cognition is the most sensitive indicator of brain function**, and is **cost effectively assessed**, this creates an enormous opportunity to improve neurologic care.
- **Annual cognitive health assessment for patients 65 years and older**
- **Assessment and treatment of factors contributing to MCI**
- Use an **objective measure** of cognition
- Periodically and routinely assessing cognitive health with **a standardized measure** is necessary... should be documented in medical records over time to **allow change in cognition to be recognized** and addressed early.
- The purpose of assessing cognitive health is not limited to identifying disease. **Cognitive impairment is a dominant comorbidity...**

Precise & Personalized Computerized Neurocognitive Testing

Adapted from: Toups, Kat et al. 'Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project'. Journal of Alzheimer's Disease, 1 Jan. 2022 : 1-11.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484109/>


CNS Vital Signs Neurocognitive Index from baseline to study conclusion



CNS Vital Signs Turns the Subjective into Objective Insight

"1 in 9 people aged 45 years and older are experiencing (SCD) Subjective Cognitive Decline"

Do you SEE the EARLY SIGNS?



^ Cognitive Aging: Progress in Understanding and Opportunities for Action; Institute of Medicine

CDC and Alzheimer's Association; Healthy Brain Initiative;
<https://www.cdc.gov/aging/healthybrain/>

Age

Source: Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs; Archives of Clinical Neuropsychology; Volume 21, Issue 7, October 2006, Pages 623-643

Join our network of clinicians and researchers.... In 50+ countries

CNS Vital Signs is Widely Used to Measure Neurocognition

...in Neurodegenerative, Neuropsychiatric, Neurotraumatic and Neurodevelopmental Disorders

Neuro

- **Memory – Healthy Aging**
 - Supports the DSM-5 Neurocognitive Disorder and MCI-Dementia-Alzheimer's Guidelines for Cognitive Assessment.
- **TBI – mTBI - Concussion**
- **Multiple Sclerosis**
- **Medication Effects**
- **Epilepsy**
- **Parkinson's**
- **Chronic Pain – Fibro Fog**
- **Sleep**

Psych

- **AD/HD**
- **Substance Use Disorder**
- **Medication Effects**
- **Bipolar**
- **Schizophrenia**
- **Depression / Anxiety**
- **PTSD**
- **Asperger's**
- **High Functioning Autism**
- **Eating Disorders**
- **Mild Hepatic Encephalopathy**

Other

- **Cancer Cognition – Chemo Brain**
- **HIV / HAND**
- **Metabolic / Diabetes**
- **Cardiovascular**
- **Prion or Lyme Disease**
- **Cardiac Surgery**
- **Diet & Exercise**
- **Occupational Health**
- **Human Performance**
- **Forensic**
- **Neurotoxicity**
- **Genetic Phenotype**

BEGIN TODAY!

In-Clinic & Telehealth Remote Neurocognitive Testing

- Broad-Spectrum Objective and Scientifically Valid & Reliable Neurocognitive Testing e.g., correlated to ApoE Polymorphisms
- Lifespan Norms Ages 8 - 90
- Millisecond Precision, Autoscored Reports with Serial Tracking
- Improve Care and Profitability with new Clinic Services e.g., ADHD, Sports Concussion, Brain Health, etc.

To learn more about the CNS VS
Neurocognitive Testing Procedure
for clinicians or
to REGISTER for a Free In Clinic Trial
go to CNS Vital Signs...

www.CNSVS.com
888.750.6941

